CX Institutional Acquires New Stake in Insulet Co. (NASDAQ:PODD)

CX Institutional acquired a new stake in Insulet Co. (NASDAQ:PODDFree Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 913 shares of the medical instruments supplier’s stock, valued at approximately $238,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Baillie Gifford & Co. lifted its holdings in Insulet by 20.7% in the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after acquiring an additional 389,639 shares during the period. Geode Capital Management LLC lifted its holdings in Insulet by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock valued at $403,339,000 after acquiring an additional 22,850 shares during the period. Clearbridge Investments LLC lifted its holdings in Insulet by 6.0% in the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock valued at $270,364,000 after acquiring an additional 75,526 shares during the period. Westfield Capital Management Co. LP lifted its holdings in Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after acquiring an additional 163,388 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Insulet by 43.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock valued at $148,091,000 after acquiring an additional 193,839 shares during the period.

Insulet Stock Up 1.1 %

PODD opened at $280.35 on Monday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market capitalization of $19.67 billion, a price-to-earnings ratio of 48.01, a price-to-earnings-growth ratio of 3.50 and a beta of 1.22. The business has a 50-day moving average of $267.25 and a two-hundred day moving average of $235.80. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $282.86.

Insulet (NASDAQ:PODDGet Free Report) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, beating the consensus estimate of $0.77 by $0.13. The company had revenue of $543.90 million during the quarter, compared to analysts’ expectations of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same quarter in the previous year, the business earned $0.71 EPS. On average, research analysts expect that Insulet Co. will post 3.22 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Citigroup raised their target price on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Canaccord Genuity Group raised their target price on Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a report on Monday, December 9th. Morgan Stanley lifted their price target on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Wells Fargo & Company lifted their price target on Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Finally, TD Cowen lifted their price target on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $272.81.

Read Our Latest Research Report on Insulet

Insulet Company Profile

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Further Reading

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDFree Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.